Piper Sandler maintains Overweight on Globus Medical, cuts target to $100
Piper Sandler analyst Matt O'Brien maintained an Overweight rating on Globus Medical but lowered the price target to $100 from $115, reflecting a revised valuation outlook.
*this image is generated using AI for illustrative purposes only.
Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on Globus Medical while lowering the price target to $100 from $115. The revised target suggests continued confidence in the company's performance despite a reduced valuation expectation.
Rating and Price Target Details
The decision to maintain the Overweight rating indicates that the firm still views the stock as likely to outperform the broader market or its sector peers. However, the reduction in the price target to $100 signals a more conservative near-term valuation compared to the previous $115 estimate.
| Metric | Value |
|---|---|
| Rating | Overweight |
| Previous Price Target | $115 |
| New Price Target | $100 |
The adjustment comes as part of a routine evaluation of the company's financial outlook and market position.
What specific factors led Piper Sandler to adopt a more conservative near-term valuation?
How might this price target reduction influence investor sentiment toward Globus Medical in the coming weeks?
What upcoming catalysts could help Globus Medical reach the revised $100 price target?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
